← Leaderboards
Mark Middleton
Starks Associates, Inc.
$5,058,723
Attributed
$5,058,723
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$5,058,723 · 2
By mechanism
N01$5,058,723 · 2
Top collaborators
No co-investigators on record.
Most similar at Starks Associates, Inc.
Same institution · by research overlap
- John Givens$6,872,993
- Walter Powell$4,396,443
- David Starks$3,757,161
Others in their field
Other Emerging Leaders on “Contracts”
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lynn Briscoe · Leidos Biomedical Research, Inc.$236,279,699
- Leonard Freedmand · Leidos Biomedical Research, Inc.$165,274,216
- Kimberly Smith · Ppd Development Lp$116,584,264
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$95,500,810
Research focus
ContractsResourcesAcquired Immunodeficiency SyndromeNational Institute Of Allergy And Infectious DiseaseIn VitroResearch StudyNovel TherapeuticsResearch Clinical TestingHepatitis C VirusPrivate SectorInvestigator-Initiated ResearchCommunitiesInvestigational New Drug ApplicationProduct DevelopmentClinical TrialsLicensureDevicesPre-ClinicalExtramural ActivitiesBasic ScienceCollaborationsHepatitis B VirusRepositoryServices
Grant awards (6)
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing$1,264,071
N01 · FY2024 · AI · contact PI
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing$1,245,214
N01 · FY2023 · AI · contact PI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases$100,023
N01 · FY2023 · AI · contact PI
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing$1,181,599
N01 · FY2022 · AI · contact PI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases$1,256,450
N01 · FY2021 · AI · contact PI
Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting$11,366
N01 · FY2021 · AI · contact PI